Kriya Therapeutics, Inc.
Kriya Therapeutics is a biopharmaceutical gene therapy company dedicated to developing accessible, life-changing gene therapies for conditions affecting millions worldwide. Their mission is to make gene therapies available for all in need, leveraging innovative approaches and a comprehensive platform for manufacturing, research, and development.
Industries
Nr. of Employees
medium (51-250)
Kriya Therapeutics, Inc.
4105 Hopson Road, Morrisville, NC 27560
Patents
Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
US-12071633-B2
View Details
Viral vector constructs for delivery of nucleic acids encoding cytokines and uses thereof for treating cancer
US-12071633-B2
View DetailsProducts
AAV-mediated gene therapy candidate for liver fibrosis (FGF21 modality)
Preclinical-stage AAV-delivered gene therapy candidate using FGF21 biology demonstrated to reverse liver fibrosis in preclinical studies.
Ophthalmology program(s) targeting geographic atrophy and thyroid eye disease
Gene therapy development programs targeting ophthalmic indications including geographic atrophy and thyroid eye disease; additional undisclosed ophthalmology programs are in the portfolio.
Metabolic disease program(s) targeting type 1 diabetes and MASH
Gene therapy programs focused on metabolic indications including type 1 diabetes and metabolic-associated steatohepatitis (MASH); additional undisclosed metabolic programs included.
Neurology program(s) targeting trigeminal neuralgia and focal epilepsy
Gene therapy programs targeting neurological indications including trigeminal neuralgia and focal epilepsy; additional undisclosed neurology programs included.
AAV-mediated gene therapy candidate for liver fibrosis (FGF21 modality)
Preclinical-stage AAV-delivered gene therapy candidate using FGF21 biology demonstrated to reverse liver fibrosis in preclinical studies.
Ophthalmology program(s) targeting geographic atrophy and thyroid eye disease
Gene therapy development programs targeting ophthalmic indications including geographic atrophy and thyroid eye disease; additional undisclosed ophthalmology programs are in the portfolio.
Metabolic disease program(s) targeting type 1 diabetes and MASH
Gene therapy programs focused on metabolic indications including type 1 diabetes and metabolic-associated steatohepatitis (MASH); additional undisclosed metabolic programs included.
Neurology program(s) targeting trigeminal neuralgia and focal epilepsy
Gene therapy programs targeting neurological indications including trigeminal neuralgia and focal epilepsy; additional undisclosed neurology programs included.
Services
In-house discovery, preclinical development, analytical and formulation development, manufacturing scale-up, and clinical development for gene therapy programs.
In-house discovery, preclinical development, analytical and formulation development, manufacturing scale-up, and clinical development for gene therapy programs.
Expertise Areas
- Gene therapy development
- Viral vector engineering and manufacturing
- Analytical development and QC for biologics
- Formulation sciences for biopharmaceuticals
Key Technologies
- AAV (adeno-associated virus) vectors
- Viral vector manufacturing
- In vivo gene delivery
- GMP-compliant cell banking
News & Updates
Kriya presented data at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
Kriya announced thirteen presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2025.
Kriya announced the publication of preclinical data demonstrating durable reversal of liver fibrosis using its investigational AAV-FGF21 gene therapy.
Kriya presented data at the 2025 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.
Kriya announced thirteen presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2025.
Kriya announced the publication of preclinical data demonstrating durable reversal of liver fibrosis using its investigational AAV-FGF21 gene therapy.